Grifols title
Contact | English | SpanishSitemap | RSS

Corporate news

IVIGs are the most important and most widely consumed plasma derived protein therapies
+ info
Manufacturing and supply agreement between Cadence Pharmaceuticals and Grifols
+ info
The Project Involved a Total Investment of 18 Million Euros
+ info

Highlights

Manufacturing

Manufacturing
We are a solid company with an international dimension.

Corporate Commitment

Social Commitment
We contribute to improving people’s health and wellbeing by offering safe, high quality products produced using the latest environmentally friendly technology.
Martín Villar
Haemostasis Awards
Grifols is holding the fifth edition of the Martin Villar Awards for Research in Haemostasis. + info
 


GRIFOLS' Websites